JAK inhibitor – Medxy AI

Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial Review

By MedXY 10/02/2026

This review synthesizes current evidence on ruxolitinib 1.5% cream efficacy and safety in cutaneous lichen planus, highlighting significant lesion and pruritus reduction in a pivotal phase 2 RCT, supporting its potential as a novel topical treatment.

Dermatology Pediatrics

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

By MedXY 10/24/2025

The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases after one year of treatment.

$Dual JAK and ROCK Inhibition with CPL’116: A Promising Advance for Methotrexate-Refractory Rheumatoid Arthritis$

Allergy & Immunology Rheumatology Specialties

Dual JAK and ROCK Inhibition with CPL’116: A Promising Advance for Methotrexate-Refractory Rheumatoid Arthritis

By MedXY 08/27/2025

CPL'116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase abnormalities associated with JAK inhibitors.